Toxicity and antitumor activity of interferon γ alone and in combinations with TNFα and melphalan in isolated limb perfusion in the BN175 sarcoma tumor model in rats

Oncology Reports

Volumn 6, Issue 1, 1999, Pages 173-177

  Manusama, Eric R ^a   De Wilt, Johannes H W ^a   Ten Hagen, Timo L M ^a   Marquet, Richard L ^a   Eggermont, Alexander M M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

IFN ; Isolated limb perfusion; Melphalan; Sarcoma; TNF

Indexed keywords

ANTINEOPLASTIC AGENT; MELPHALAN; RECOMBINANT GAMMA INTERFERON; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTICLE; BROWN NORWAY RAT; CANCER TRANSPLANTATION; DRUG SCREENING; HINDLIMB; MALE; RAT; REGIONAL PERFUSION; SARCOMA; SOFT TISSUE TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DRUG SCREENING ASSAYS, ANTITUMOR; HINDLIMB; INTERFERON-GAMMA, RECOMBINANT; MALE; MELPHALAN; NEOPLASM TRANSPLANTATION; RATS; RATS, INBRED BN; RECOMBINANT PROTEINS; SARCOMA, EXPERIMENTAL; SOFT TISSUE NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032621403     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Liénard D, Ewalenko, Delmotte JJ, Renard N and Lejeune FJ: High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 62: 10-50, 1992.
2. Lejeune FJ, Liénard D, Leyvraz S and Mirimanoff RO: Regional therapy of melanoma. Eur J Cancer 29A: 606-612, 1993.
3. Eggermont AMM: Treatment of melanoma in-transit metastases confined to the limb. Cancer Surv 26: 335-347, 1996.
4. Eggermont AMM, Schraffordt Koops H, Lienard D, Kroon BBR, van Geel AN, Hoekstra HJ and Lejeune FJ: Isolated limb perfusion with high dose tumor necrosis factor-α in combination with IFNγ and melphalan for irresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 14: 2653-2665, 1996.
5. Eggermont AMM, Schraffordt Koops H, Klausner JM, Kroon BBR. Schlas PM, Liénard D, Geel van AN, Hoekstra HJ, Meller I, Nieweg OE, Kettelhack C, Ben-Ari G, Pector J-C and Lejeune FJ: Isolated limb perfusion with tumor necrosis factor and melphalan in 186 patients wiht locally advanced soft tissue extremity sarcomas: the cumulative multicenter European experience. Ann Surg 224; 756-765, 1996.
6. Aggarwal BB, Eessalu TE and Hass PE: Characterization of receptors for human tumor necrosis factor and their regulation by interferon-γ. Nature 318: 665-667, 1985.
7. Ruggiero V, Tavernier J, Fiers W, et at: Induction of the synthesis of tumor necrosis factor receptors by interferon-γ. J Immunol 136: 2445-2450, 1986.
8. Fiers W, Brouckaert P and Guisez Y, et al: Recombinant Interferon γ and its synergism with tumor necrosis factor in the human and mouse systems. In: The Biology of the Interferon System. Schellekens H, Stewart WE (eds). Elsevier Science, Amsterdam, pp241-248, 1986.
9. Sohmura Y: Antitumor effect of recombinant human tumor necrosis factor α and its augmentation in vitro and in vivo. In: Tumor Necrosis Factor/Cachectin and related Cytokines. Bonavida B, Gifford GE, Kirchner H, et al (eds). Karger, Basel, pp 189-195, 1988.
10. de Kossodo S, Moore R, Gschmeissner S, East N, Upton C and Balkwill FR: Changes in endogenous cytokines, adhesion molecules and platelets during cytokine-induced tumour necrosis. Br J Cancer 72: 1165-1172, 1995.
11. Sato N, Goto T, Haranaka K, Satomi N, Nariuchi H, ManoHirano Y and Sawasaki Y: Actions of TNF on cultured vascular endothelial cells: morphological modulation, growth inhibition and cytotoxicity. J Natl Cancer Inst 76: 1113-1117, 1986.
12. Watanabe N, Niitsu Y, Umeno H, Sone H, Neda H, Yamauchi N, Maeda M and Urushizaki I: Toxic effect of TNF on tumor vasculature in mice. Cancer Res 49: 2179-2183, 1988.
13. Nawroth P, Handley D, Matsueda G, DeWaal G, Gerlach H, Blohm D and Stern D: TNF/Cachectin-induced intravascular tibrin formation in Meth-A fibrosarcomas. J Exp Med 168: 637-647, 1988.
14. Fajardo LF, Kwan HH, Kowalski J, et al: Dual role of tumor necrosis factor-α in angiogenesis. Am J Pathol 140: 539-544, 1992.
15. Asher AL, Mule JJ, Reichert CM, el al: Studies of the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 138: 963-974, 1987.
16. Benckhuijsen C, Kroon BBR, van Geel AN and Wieberdink J: Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J Surg Oncol 14: 157-163, 1988.
17. Eggermont AMM. Schraffordt Koops H, Lienard D, Lejeune FJ and Oukerk M: Angiographic observations before and after high dose TNF isolated limb perfusion in patients with extremity soft tissue sarcomas. Eur J Surg Oncol 20: 323-324, 1994.
18. Manusama ER, Nooijen PTGA, Stavast J, Durante NMC. Marquet RL and Eggermont AMM. Synergistic antitumour effect of recombinant human tumour necrosis factor-α with melphalan in isolated limb perfusion in the rat. Br J Surg 83: 551-555, 1996.
19. Nooijen PTGA, Manusama ER, Eggermont AMM, Schalkwijk van L, Waal de RMW, Marquet RL and Ruiter DJ: Synergistic antitumour effects of TNF-α and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathologic, immunohistochemical and electron microscopic study. Br J Cancer 74: 1908-1935, 1996.
20. Manusama ER, Stavast J, Durante NMC. Marquet RL and Eggermont AMM: Isolated limb perfusion in a rat osteosarcoma model: a new anti-tumour approach. Eur J Sure Oncol 22: 152-157, 1996.
21. Marquet RL, Schellekens H, Westbroek DL and Jeekel J: Effect of treatment with interteron and cyclophosphamide on the growth of a spontaneous liposarcoma in rats. Int J Cancer 31: 223-226, 1983.
22. Kort WJ, Zondervan PE, Hulsman LO, Weijma IM and Westbroek DL: Incidence of spontaneous tumors in a group of retired breeder female brown Norway rats. J Natl Cancer Inst 72: 709-713, 1984.
23. Prehn RT and Main JW: Immunity to methylcholantrene induced sarcomas. J Natl Cancer Inst 18: 769-778, 1957.
24. Kramer SM and Carver ME: Serum-free in vitro bioassay for the detection of tumor necrosis factor. J Immunol Methods 93: 201-206, 1986.
25. Dijkman R, van der Meide PH, Pouwels PH, Caspers M, Dubbeld M and Schellekens H: Cloning and Expression of the chromosomal immune interteron sene of the rat. EMBO J 4: 461-467, 1985.
26. Marquet RL, Westbroek DL and Jeekel J: Interferon treatment of a transplantable rat colon adenocarcinoma: importance of tumor site. Int J Cancer 33: 689-692, 1984.
27. Manusama ER, Durante NMC, Marquet RL and Eggermont AMM: Ischemia promotes the antitumor effect of tumor necrosis factor α (TNFα) in isolated limb perfusion in the rat. Reg Cancer Treat 7: 155-159, 1994.
28. Renard N, Liénard D, Lespagnard L, Eggermont AMM, Heimann R and Lejeune FJ: Early endothelium activation and polymorphonucleas cell invasion procede specific necrosis of human melanoma and sarcoma treated by intravascular high dose tumor necrosis factor α. Int J Cancer 57: 656-663, 1994.
29. Renard N, Nooijen PTGA, Schalkwijk L, Waal de RMW, Eggermont AMM, Lienard D, Kroon BBR, Lejeune FJ and Ruiter DJ: VWF release and platelet aggregation in human melanoma after perfusion with TNFα. J Pathol 176: 279-287, 1995.
30. Kristensen CA, Nozue M, Boucher Y and Jain RK: Reduction of interstitial fluid pressure after TNFα treatment of three human melanoma xenografts. Br J Cancer 64: 533-536, 1996.
31. Talmedge JE, Bowersox O, Tribble H, Lee SH, Shepard HM and Liggitt D: Toxicity of tumor necrosis factor is synergistic with samma-interferon and can be reduced with cyclooxygenase inhibitors. Am J Pathol 128: 410-425, 1987.
32. Ruegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P and Lejeune FJ: Evidence for the involvement of endothelial cell integrin αVβ3 in the disruption of the tumor vasculature induced by TNF and IFNγ. Nat Med 4: 408-414, 1998.